undamentalytics Newsletter
Sign in

Collegium Pharmaceutical, Inc income statement

In fiscal 2025, Collegium Pharmaceutical, Inc reported revenue of $781m, up 23.6% on the year before, operating income of $180m (a 23.0% margin) and net income of $62.9m, or $1.73 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue228280297310277464567631781808
Cost of revenue03166194130126254241254317323
Gross profit126115103180151209326377463485
Research and development159910109400——
Selling, general and administrative8193127116114119172159210285328
Operating income−94−75−21−24561833167170180157
Interest expense0—20129216383748276
Income before tax——−39−2328−3−2976999358
Income tax———01−75−42829306
Net income−94−75−39−232772−2548696334
Diluted EPS−$3.88−$2.47−$1.19−$0.68$0.76$1.86−$0.74$1.29$1.86$1.73$0.88
Diluted shares (average)24m30m33m33m35m41m34m42m40m40m38m
EBITDA−93−75−20−23571936170174184162

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: COLL vs CORTCOLL vs SUPNAXSM vs COLL

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Collegium Pharmaceutical, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Collegium Pharmaceutical, Inc.